PMID- 36556428
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221226
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 12
IP  - 12
DP  - 2022 Dec 8
TI  - High Post-Treatment Leptin Concentration as a Prognostic Biomarker of the High 
      Risk of Luminal Breast Cancer Relapse: A Six-Year Comprehensive Study.
LID - 10.3390/life12122063 [doi]
LID - 2063
AB  - (1) Background: Nowadays, obesity is well-recognised as a significant risk factor 
      for many chronic diseases, for example, hypertension, diabetes, atherosclerosis 
      and cancer. This study is designed to investigate the prognostic value of the 
      pre- and post-treatment serum levels of adiponectin and leptin in luminal A and B 
      invasive breast cancer (IBrC) patients based on six-years follow-up. (2) Methods: 
      Among 70 patients who underwent breast surgery, 35 were Stage I and 35 were Stage 
      II. The concentrations of pre- and post-treatment adiponectin and leptin were 
      evaluated with a specific ELISA kit. The median follow-up was 68.5 months 
      (inter-quartile range (IQR) = 59-72 months) with a recurrence rate of 15.71%. (3) 
      Results: Generally, concentrations of leptin and adiponectin increased after 
      adjuvant therapy. Follow-up showed a significantly higher incidence of disease 
      relapse in IBrC patients with a high post-treatment concentration of leptin 
      (25.71% vs. 5.71% of cases with a low post-treatment concentration of leptin). A 
      post-treatment leptin concentration of 26.88 ng/mL with a specificity of 64.9% 
      and a sensitivity of 88.9% was determined as the best cut-off value to 
      distinguish patients with disease recurrence from those without disease relapse. 
      (4) Conclusions: Our results demonstrated that only the post-treatment serum 
      leptin concentration may be of value as a prognostic indicator and could 
      contribute to predicting a future outcome for patients with early-stage IBrC.
FAU - Kwiatkowska, Katarzyna
AU  - Kwiatkowska K
AD  - Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus 
      University, Collegium Medicum, 85-094 Bydgoszcz, Poland.
FAU - Rhone, Piotr
AU  - Rhone P
AD  - Clinical Ward of Breast Cancer and Reconstructive Surgery, Oncology Centre Prof. 
      F. Lukaszczyk Memorial Hospital, 85-796 Bydgoszcz, Poland.
FAU - Wrzeszcz, Katarzyna
AU  - Wrzeszcz K
AD  - Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus 
      University, Collegium Medicum, 85-094 Bydgoszcz, Poland.
FAU - Ruszkowska-Ciastek, Barbara
AU  - Ruszkowska-Ciastek B
AUID- ORCID: 0000-0003-4245-2403
AD  - Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus 
      University, Collegium Medicum, 85-094 Bydgoszcz, Poland.
LA  - eng
PT  - Journal Article
DEP - 20221208
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC9783731
OTO - NOTNLM
OT  - adiponectin
OT  - breast cancer
OT  - leptin
OT  - relapse
OT  - treatment
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/24 06:01
PMCR- 2022/12/08
CRDT- 2022/12/23 01:40
PHST- 2022/10/22 00:00 [received]
PHST- 2022/11/30 00:00 [revised]
PHST- 2022/12/05 00:00 [accepted]
PHST- 2022/12/23 01:40 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/24 06:01 [medline]
PHST- 2022/12/08 00:00 [pmc-release]
AID - life12122063 [pii]
AID - life-12-02063 [pii]
AID - 10.3390/life12122063 [doi]
PST - epublish
SO  - Life (Basel). 2022 Dec 8;12(12):2063. doi: 10.3390/life12122063.